DSM Biologics and Crucell Announce PER.C6® Licensing Agreement with
Daiichi Sankyo Ltd.
Sittard/Leiden, The Netherlands, November 16, 2007 - DSM Biologics, a
business unit of DSM Pharmaceutical Products and Dutch biotechnology
company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX)
today announced a PER.C6® license agreement with Daiichi Sankyo Ltd.
(Tokyo Stock Exchange Ticker 4568). This license agreement allows
Daiichi Sankyo to use the PER.C6® cell line in their early stage
research to identify new antibodies and for the production of
preclinical grade material. Financial details were not disclosed.
About the PER.C6® Technology Platform
Crucell's PER.C6® technology platform has been developed for the
large-scale manufacture of biopharmaceutical products such as
recombinant proteins including monoclonal antibodies. Compared to
conventional production technologies, the strengths of PER.C6®
technology lie in its excellent safety profile, scalability and
productivity under serum-free culture conditions.
About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
biotechnology company focused on research, development and worldwide
marketing of vaccines and antibodies that prevent and treat
infectious diseases. Its vaccines are sold in public and private
markets worldwide. Crucell's core portfolio includes a vaccine
against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against
influenza. Crucell also markets travel vaccines, such as the only
oral anti-typhoid vaccine, an oral cholera vaccine and the only
aluminium-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several Crucell products based on
its unique PER.C6® production technology. The Company licenses this
and other technologies to the biopharmaceutical industry. Important
partners and licensees include DSM Biologics, Sanofi Aventis,
Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden
(The Netherlands), with subsidiaries in Switzerland, Spain, Italy,
Sweden, Korea and the US. The Company employs over a 1000 people. For
more information, please visit www.crucell.com
About DSM Biologics
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a
global provider of manufacturing technology and services to the
biopharmaceutical industry. In addition to offering world-class
biopharmaceutical manufacturing services, DSM Biologics has
co-exclusive rights, along with Dutch biotech company Crucell N.V.,
to license the high-producing PER.C6® human cell line as a production
platform for recombinant proteins and monoclonal antibodies. DSM
Biologics' FDA-approved facility in Groningen, The Netherlands, was
established in 1986 and has a strong track record in using a broad
range of cell lines (PER.C6®, CHO, hybridoma, etc.) in
biopharmaceutical manufacturing, and has a wide range of experience
using multiple manufacturing (batch, fed-batch and continuous
perfusion) and purification techniques. The combination of the
PER.C6® human cell line and DSM's manufacturing services provides
companies with a turn-key biologic manufacturing solution reducing
cost, risk and time to market. DSM Biologics is represented in Japan
by Asahi Glass & Co, Ltd. For more information, please visit
www.dsmbiologics.com
About DSM
DSM creates innovative products and services in life sciences and
materials sciences, contributing to the quality of life. DSM's
products and services are used globally in a wide range of markets
and applications, supporting a healthier, more sustainable and
enjoyable way of living. End markets include human and animal
nutrition and health, personal care, pharmaceuticals, automotive,
coatings and paint, electrics & electronics, life protection and
housing. The company strategy, Vision 2010 - Building on Strengths,
focuses on accelerating profitable and innovative growth of the
company's specialties portfolio. The key drivers of this strategy are
market-driven growth and innovation, an increased presence in
emerging economies and operational excellence. DSM has annual sales
of almost EUR 9 billion and employs some 22,000 people worldwide. The
company is headquartered in the Netherlands, with locations in
Europe, Asia, the Americas, Africa and Australia. More information on
DSM can be found at www.dsm.com.
For further information please contact:
DSM Pharmaceutical Products
Karen King Crucell N.V. Media:
President Barbara Mulder
DSM Biologics Director Corporate Communications
+1-973-257-8427 Tel: +31-(0) 71 519 7346
Karen.King@dsm.com press@crucell.com
DSM Biologics
Marcel Lubben Investors/Analysts:
Vice President Oya Yavuz
Marketing, Sales & NBD Director Investor Relations
(+31) 46 47 73343 Tel. +31-(0) 71-519 7064
marcel-m.lubben@dsm.com ir@crucell.com
www.crucell.com
Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. These statements are based on
current expectations, estimates and projections of the management of
DSM and Crucell and information currently available to both
companies. The statements involve certain risks and uncertainties
that are difficult to predict and therefore DSM and Crucell do not
guarantee that their expectations will be realized. Furthermore, DSM
and Crucell have no obligation to update the statements contained in
this press release.
Crucell has identified certain important factors that may cause
actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors
please refer to the Form 20-F, as filed by Crucell with the U.S.
Securities and Exchange Commission on June 13, 2007, and the section
entitled "Risk Factors". Crucell prepares its financial statements
under generally accepted accounting principles in the United States
(US GAAP) and Europe (IFRS).